Acamprosate Calcium
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
Major Pharmaceuticals
Acamprosate Calcium
Listed by Glenmark Pharmaceuticals Inc., USA
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
- Route
- Oral
What it contains
- Acamprosate Calcium 333 mg/1
FDA record
| Dosage form | Tablet, Delayed Release |
|---|---|
| Route | Oral |
| Approval route | ANDA — approved generic |
| NDC code | 68462-435 |
| FDA application | ANDA202229 |
| RxNorm concept | 835726 |
| Package sizes listed | 2 |
| Marketed since | July 2013 |
Other products containing Acamprosate
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Acamprosate Calcium
acamprosate calcium enteric-coated
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
Mylan Pharmaceuticals Inc.
Acamprosate Calcium
acamprosate calcium enteric-coated
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
NCS HealthCare of KY, LLC dba Vangard Labs
Acamprosate Calcium
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
Bionpharma Inc.,
acamprosate calcium
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
Zydus Lifesciences Limited
acamprosate calcium
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
Zydus Pharmaceuticals (USA) Inc.
Acamprosate Calcium
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
American Health Packaging
ACAMPROSATE CALCIUM
- Strength
- 333 mg/1
- Form
- Tablet, Delayed Release
Somerset Therapeutics, LLC
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.